Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Share-based Compensation (2019 - 2025)

Pulmonx (LUNG) has disclosed Share-based Compensation for 7 consecutive years, with $5.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation fell 11.53% to $5.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $22.5 million, a 2.24% decrease, with the full-year FY2024 number at $23.0 million, up 3.86% from a year prior.
  • Share-based Compensation was $5.2 million for Q3 2025 at Pulmonx, down from $6.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $6.2 million in Q2 2025 to a low of $2.3 million in Q1 2021.
  • A 5-year average of $4.7 million and a median of $5.2 million in 2025 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: skyrocketed 1354.09% in 2021, then fell 11.53% in 2025.
  • Pulmonx's Share-based Compensation stood at $3.0 million in 2021, then soared by 41.0% to $4.2 million in 2022, then surged by 31.81% to $5.6 million in 2023, then fell by 1.34% to $5.5 million in 2024, then fell by 6.46% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Share-based Compensation are $5.2 million (Q3 2025), $6.2 million (Q2 2025), and $5.6 million (Q1 2025).